Laurus Labs has infused further equity into its wholly-owned subsidiary Laurus Synthesis (LSPL) via subscribing to the rights issue offered by LSPL for a cash consideration of Rs 99,13,12,308 for acquisition of 7,600 Equity shares of Rs 10 each at a premium of Rs 1,30,425.83 per share.
The Company has infused further equity via rights issue keeping in view of the funds requirements of LSPL. The Company has paid the share application money and 7600 Equity shares of Rs 10 each were allotted.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1502.30 |
Dr. Reddys Lab | 6198.90 |
Cipla | 1402.20 |
Zydus Lifesciences | 957.00 |
Lupin | 1645.00 |
View more.. |